Nanotherapeutics, Takeda deal

The partners will expand Takeda’s commercialization and technology access rights related to Nanotherapeutics’ Vero cell culture technology. The agreement will eliminate Takeda’s financial obligation to Baxter International Inc. (NYSE:BAX, Deerfield, Ill.), from which Takeda acquired Japanese rights to the technology to develop an H5N1 influenza vaccine under a December 2010 deal. Nanotherapeutics acquired the Vero cell culture technology from Baxter in 2014. ...